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A B S T R A C T   
Leimyosarcomas arising from the stroma of the prostate are very rare, accounting for 0.1% of malignancies. We 
describe a case that closely mimicked benign prostatic hypertrophy on magnetic resonance imaging. Due to the 
low incidence of disease there is no high level evidence for management. We advocate neoadjuvant radiotherapy 
followed by radical prostatectomy with pelvic lymph node dissection. Diagnosis and expedient management is 
critical.   
Introduction 
Leiomyosarcoma of the prostate is a rare malignancy accounting for 
0.1% of prostate malignancies.1 It was first described in 1853 and En-
glish literature searches show case reports from 1950 onwards, since 
then there have been less than 200 cases reported globally.2 Although 
rare, clinicians must be aware of this aggressive malignancy with a 
median survival of 17 months and 5-year survival rates of 26%.2,3 They 
effect male patients of all ages from 2 to 80 years.2–5 
Case presentation 
A 58 year old man with no significant past medical history presented 
to his local doctor with exacerbation of pre-existing lower urinary tract 
symptoms, most notably increased frequency and nocturia. Previous 
investigations, 4 years earlier, were unremarkable. He was an active 
man who took no regular medication, was a non-smoker, and had no 
surgical history. 
Prostate specific antigen (PSA) was 2.2ng/ml, creatinine 85 μmol 
eGFR 87ml/min/1.73m2. Ultrasound studies showed prostatomegaly 
(62 cc), and new elevated post micturition volume of 108ml with a 
thickened trabeculated bladder. Significantly, the prostate demon-
strated a hypoechoic solid lesion arising from the right-side of the gland 
measuring 24  26  23mm, which was not present 4 years earlier 
(Fig. 1). 
The patient was referred to an urologist who performed a digital 
rectal exam which was benign. Multi-parametric magnetic resonance 
imaging of the prostate was obtained, revealing a right-sided para-
prostatic nodule (2.9 2.1  2.5cm). The lesion was in contact with the 
bladder and obturator internus muscle with no invasion. It was het-
erogeneous and on T2 imaging resembled identical morphology to the 
hypertrophied transition zone, with presumed stromal and glandular 
elements within (Fig. 2a). However, on the high B value DWI, there was 
elevated signal within the stromal elements and restricted signal on the 
ADC to around 800 (Fig. 2b). The enhancement is heterogeneous on the 
DCE similar to the transition zone. There was no targetable lesion within 
the prostate. There was no extracapsular extension or abnormal pelvic 
nodes. 
A CT-guided biopsy was performed and three 18-gauge core biopsy 
were obtained. All cores comprised of entirely lesional material with no 
prostatic tissue observed. Cores were composed of highly atypical 
spindle cells arranged in intersecting fascicles. The cells had elongated, 
hyperchromatic, pleomorphic nuclei and abundant densely eosinophilic 
cytoplasm. There were numerous apoptotic nuclei and mitotic figures 
seen, numbering up to 2 per 10HPF. There was no tumour necrosis. 
Cells were strongly and diffusely positive for SMA and desmin. CD34 
showed patchy positivity. S100 and SOX-10 were negative. The Ki-67 
proliferative index was variable, up to 20% in the highest areas. 
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Fig. 1. Ultrasound transverse view of prostate (green line) A) 07/08/2015, B) 25/06/2019 with new lesion arising from right lobe (red line). (For interpretation of 
the references to colour in this figure legend, the reader is referred to the Web version of this article.) 
Fig. 2. MRI axial views with prostate in green and lesion in red A) T2, B) ADC. (For interpretation of the references to colour in this figure legend, the reader is 
referred to the Web version of this article.) 
Fig. 3. Haematoxylin and Eosin stain 10 (left); Anatomical pathology specimen viewed from right lateral with lesion on left of picture and apex of prostate on right 
of picture (right). 
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A computed tomography (CT) scan of the patient’s chest and FDG- 
PET scan was performed for staging, which revealed no avid visceral 
or nodal metastases and moderate grade peripheral metabolic activity in 
the leiomyosarcoma. The patient was referred to a dedicated sarcoma 
multidisciplinary meeting. The decision for neoadjuvant radiation 
therapy (50.4Gy, 28 fractions) followed by a robotic assisted radical 
prostatectomy (RARP) was decided. Following radiotherapy subsequent 
imaging showed interval necrosis of the tumour, which remained PET- 
avid. RARP and right pelvic lymph node dissection was performed five 
weeks post completion of radiotherapy, which was unremarkable, 
adhering to minimal tissue handling with wide margins (Fig. 3). 
Final histology showed a 58mm tumour, which was upgraded from 
the original biopsy from grade 2 to grade 3 leiomyosarcoma. Margins 
were clear with no infiltration of seminal vesicles, fat planes present, and 
a medial margin formed by the prostate with no infiltration. Nodes were 
reactive with no metastases detected. 
Discussion 
Although rare, accounting for less than 0.1% of prostate malig-
nancies clinicians need to be mindful of this aggressive disease.5 Prostate 
leiomyosarcomas are a subgroup of sarcomas affecting the prostate, 
which include rhabdomyosarcomas, carcinosarcomas, and unspecified. 
Leiomyosarcomas are difficult to identify on MRI as they resemble 
benign prostatic hypertrophy (BPH) on T2 imaging and heterogeneously 
enhance on DCE much like the transition zone. This may make intra-
glandular prostatic lesions difficult to identify. However, on the high B 
value DWI, there is elevated signal within the stromal elements and 
restricted signal on the ADC to around 800 reflecting the hyper-
cellularity of these tumours, making them somewhat suspicious. This 
coupled with a low PSA may delay diagnosis contributing to poor out-
comes. MRI for evaluation of patients with suspected prostate cancer has 
become standard of care and is supported by a large body of evidence. If 
the lesion had been confined to the transition zone, based upon PIRADS 
version 2 it would have been classified as a PIRADS 2 lesion and avoided 
biopsy. In PIRADS version 2.1 the role of DWI in the transition zone has 
been expanded and would have upgraded this lesion to a PIRADS 3. 
However given the low PSA the patient would still be unlikely to have 
undergone biopsy. We were fortunate with this patient given the 
exophytic nature of his lesion. 
Most cases have been treated with external beam radiotherapy as 
more common sarcomas are known to be radiosensitive, however, there 
is not enough literature to support this and treatment is fiduciary and 
empirical.5 Despite the prompt detection and subsequent management 
this patient’s sarcoma was upgraded on final histology, which highlights 
the aggressiveness and timely manner this tumour must be managed. 
Published survival outcomes are poor but with a 17 month median but it 
is hoped our patient will fare better. We have proposed annual follow up 
with FDG-PET alternating with MRI. At the time of writing he is six 
months from original biopsy, and recovered well from his treatment. 
Conclusion 
Leiomyosarcomas of the prostate are rare. They often present with 
non-specific urinary tract symptoms, most commonly increased urinary 
frequency. Unless exophytic, diagnosis remains challenging on imaging 
and delay may be increased due to normal PSA levels and standard 
investigation algorithms. Due to the rare nature of this disease there is 
no consensus on best management approach. We recommend consul-
tation of experienced sarcoma teams for guidance. This case will add to 
the literature so that an eventual treatment algorithm can emerge. 
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